

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Date: 11.05.2023

To,

BSE Limited 25th Floor Phiroze Jeejebhoy Towers Dalal Street, Mumbai 400 001 BSE Code-531146	National Stock Exchange of India Limited Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai – 400 051 NSE Code: MEDICAMEQ
--	--

Re: Declaration under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the financial year ended March 31, 2023

Dear Sir/Madam,



In compliance with the provisions of regulation 31 (4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SAST Regulations”), please find enclosed herewith the annual disclosures submitted by the Promoters and Promoter group of the Company for the year ended March 31, 2023.

The above information will also be made available on the website of the Company at www.medicamen.com.

We request you to kindly take the above on record and acknowledge receipt.

Yours sincerely,

**For and on behalf of
Medicamen Biotech Limited**

Parul Choudhary
Company Secretary
ACS44157

Date: 10.05.2023

To,

BSE Limited 25th Floor Phiroze Jeebhoy Towers Dalal Street, Mumbai 400 001 BSE Code-531146	National Stock Exchange of India Limited Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai – 400 051 NSE Code: MEDICAMEQ	The Chairman Audit Committee Medicamen Biotech Limited 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi- 110019
--	---	---

Re: Declaration under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir/Madam,

This letter sets out the declaration being made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ('SAST Regulation') by Shivalik Rasayan Limited and Growel Remedies Limited in respect of their shareholding in Medicamen Biotech Limited. ("Target Company").

In compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ('SAST Regulation'), we declare that the Medicamen's Promoter Shareholders (along with persons acting in concert) have not made any encumbrance, directly or indirectly, during the financial year ended March 31, 2023 on the shares held by us in the Company.


We request you to kindly take the above on record and acknowledge receipt.

Kindly take the same on record.

for and on behalf of

Shivalik Rasayan Limited

For Shivalik Rasayan Limited



Director

Ashwani Kumar Sharma

Director

for and on behalf of

Growel remedies Limited

For Growel Remedies Limited



Director

Rahul Bishnoi

Director